See more : Fraport AG (FPRUY) Income Statement Analysis – Financial Results
Complete financial analysis of Daré Bioscience, Inc. (DARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Daré Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Endurance Gold Corporation (ENDGF) Income Statement Analysis – Financial Results
- Digital Arts Inc. (2326.T) Income Statement Analysis – Financial Results
- Bowlero Corp. (BOWL) Income Statement Analysis – Financial Results
- Dune Acquisition Corporation (DUNEW) Income Statement Analysis – Financial Results
- Omagine, Inc. (OMAGQ) Income Statement Analysis – Financial Results
Daré Bioscience, Inc. (DARE)
About Daré Bioscience, Inc.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.81M | 10.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 766.00K | 0.00 | 80.00K | 6.00K | 625.00K | 305.00K |
| Cost of Revenue | 38.36K | 47.62K | 26.41K | 43.23K | 11.14K | 2.44K | 0.00 | 400.00K | 192.00K | 0.00 | 0.00 | 0.00 | 363.00K |
| Gross Profit | 2.77M | 9.95M | -26.41K | -43.23K | -11.14K | -2.44K | 0.00 | 366.00K | -192.00K | 80.00K | 6.00K | 625.00K | -58.00K |
| Gross Profit Ratio | 98.63% | 99.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 47.78% | 0.00% | 100.00% | 100.00% | 100.00% | -19.02% |
| Research & Development | 21.54M | 30.04M | 30.62M | 20.77M | 8.55M | 6.41M | 984.75K | 27.57M | 25.95M | 11.77M | 9.70M | 15.81M | 13.49M |
| General & Administrative | 12.11M | 11.24M | 8.45M | 6.63M | 5.80M | 5.28M | 2.70M | 10.36M | 11.22M | 8.59M | 6.17M | 6.39M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.11M | 11.24M | 8.45M | 6.63M | 5.80M | 5.28M | 2.70M | 10.36M | 11.22M | 8.59M | 6.17M | 6.39M | 5.34M |
| Other Expenses | 0.00 | 100.00K | 2.52K | 1.51K | 81.05K | 143.50K | 7.49B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 33.61M | 41.39M | 39.07M | 27.40M | 14.34M | 11.69M | 3.69M | 37.92M | 37.17M | 20.36M | 15.87M | 22.20M | 18.82M |
| Cost & Expenses | 33.75M | 41.39M | 39.07M | 27.40M | 14.34M | 11.69M | 3.69M | 37.92M | 37.17M | 20.36M | 15.87M | 22.20M | 19.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 10.00K | 9.00K | 2.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 322.63K | 2.24M | 2.43M | 1.08M | 1.49M | 567.00K | 26.00K |
| Depreciation & Amortization | 38.36K | 47.62K | 26.41K | 43.23K | 11.14K | 2.44K | 2.73M | 261.00K | 192.00K | 126.00K | 197.00K | 346.00K | 363.00K |
| EBITDA | -30.90M | -31.36M | -39.04M | -27.36M | -14.33M | -11.69M | -11.18M | -36.81M | -36.97M | -22.13M | -15.46M | -21.19M | -18.55M |
| EBITDA Ratio | -1,100.53% | -313.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,805.09% | 0.00% | -25,180.00% | -261,016.67% | -3,396.32% | -6,082.95% |
| Operating Income | -30.84M | -31.39M | -39.07M | -27.40M | -14.34M | -16.88M | -11.18M | -37.15M | -37.17M | -20.28M | -15.86M | -21.58M | -18.88M |
| Operating Income Ratio | -1,098.33% | -313.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,850.39% | 0.00% | -25,348.75% | -264,333.33% | -3,452.00% | -6,189.51% |
| Total Other Income/Expenses | 678.49K | 437.75K | 372.41K | 1.51K | 81.05K | 143.50K | -322.63K | -2.15M | -2.42M | -3.06M | -1.28M | -526.00K | -64.00K |
| Income Before Tax | -30.16M | -30.95M | -38.70M | -27.40M | -14.26M | -16.74M | -11.50M | -39.31M | -39.59M | -23.34M | -17.14M | -22.10M | -18.94M |
| Income Before Tax Ratio | -1,074.17% | -309.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,131.20% | 0.00% | -29,177.50% | -285,716.67% | -3,536.16% | -6,210.49% |
| Income Tax Expense | 0.00 | -437.75M | -369.89K | -163.07K | -160.72K | 10.23M | -7.17M | 86.00K | 10.00K | 1.08M | 1.49M | 567.00K | 0.00 |
| Net Income | -30.16M | -30.95M | -38.33M | -27.40M | -14.26M | -26.97M | -11.50M | -39.31M | -39.59M | -23.34M | -17.14M | -22.10M | -19.56M |
| Net Income Ratio | -1,074.17% | -309.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,131.20% | 0.00% | -29,177.50% | -285,716.67% | -3,536.16% | -6,414.10% |
| EPS | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| EPS Diluted | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| Weighted Avg Shares Out | 7.28M | 7.05M | 5.10M | 2.51M | 1.30M | 894.37K | 269.36K | 69.21K | 2.54M | 1.45M | 1.90M | 78.70K | 73.16K |
| Weighted Avg Shares Out (Dil) | 7.28M | 7.05M | 5.10M | 2.51M | 1.30M | 894.37K | 269.36K | 69.58K | 0.00 | 1.45M | 1.90M | 78.70K | 73.16K |
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Daré Bioscience Announces Reverse Stock Split
Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports